Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Black Diamond Therapeutics (BDTX) Non-Current Assets (2018 - 2025)

Black Diamond Therapeutics' Non-Current Assets history spans 6 years, with the latest figure at $10.6 million for Q4 2025.

  • For Q4 2025, Non-Current Assets fell 50.75% year-over-year to $10.6 million; the TTM value through Dec 2025 reached $69.5 million, down 23.39%, while the annual FY2025 figure was $10.6 million, 50.75% down from the prior year.
  • Non-Current Assets reached $10.6 million in Q4 2025 per BDTX's latest filing, down from $18.7 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $32.6 million in Q3 2021 to a low of $10.6 million in Q4 2025.
  • Average Non-Current Assets over 3 years is $20.5 million, with a median of $20.6 million recorded in 2025.
  • The largest YoY upside for Non-Current Assets was 2119.25% in 2021 against a maximum downside of 88.01% in 2021.
  • A 3-year view of Non-Current Assets shows it stood at $32.6 million in 2021, then crashed by 34.12% to $21.5 million in 2024, then plummeted by 50.75% to $10.6 million in 2025.
  • Per Business Quant, the three most recent readings for BDTX's Non-Current Assets are $10.6 million (Q4 2025), $18.7 million (Q3 2025), and $19.7 million (Q2 2025).